Welcome to our dedicated page for ASTRAZENECA PLC SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRAZENECA PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRAZENECA PLC's regulatory disclosures and financial reporting.
AstraZeneca PLC reported strong full-year 2025 results with broad-based growth. Total Revenue rose to $58,739m, up 8% at constant exchange rates, led by Oncology, BioPharmaceuticals and Rare Disease. Reported EPS increased to $6.60, up 43% at constant exchange rates, while Core EPS grew 11% to $9.16.
The company highlighted 16 positive Phase 3 readouts and 43 major approvals over the last 12 months and now counts 16 blockbuster medicines. A total dividend of $3.20 per share for 2025 was declared, up 3%, with an intended increase to $3.30 per share in 2026.
For 2026, AstraZeneca guides to mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS growth at constant exchange rates, with a Core tax rate of 18–22%. The company also began trading ordinary shares on the NYSE, announced $15bn of planned investment in China through 2030, and signed major pipeline and collaboration deals, including a $1.2bn upfront weight‑management portfolio agreement with CSPC and sizeable oncology transactions with Jacobio Pharma and AbelZeta.
AstraZeneca reports that the US FDA issued a complete response letter for the Biologics License Application for subcutaneous Saphnelo in adults with systemic lupus erythematosus, but the company has submitted additional information and expects an FDA decision in the first half of 2026.
The subcutaneous form is supported by the Phase III TULIP-SC trial, which met its primary endpoint of reducing disease activity with a safety profile consistent with the approved IV formulation. Subcutaneous Saphnelo is already approved in the European Union for adults with moderate to severe lupus.
Saphnelo IV is approved in more than 70 countries, and more than 40,000 patients have been treated globally. Under an updated 2025 agreement, AstraZeneca will pay Bristol-Myers Squibb a mid-teens royalty on US Saphnelo sales.
AstraZeneca PLC reports its updated share capital and voting rights position. As at 31 January 2026, the company has 1,550,944,612 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, giving the same total number of voting rights.
This figure is provided so shareholders can use it as the denominator when calculating whether they must notify their holdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been recommended for EU approval as a perioperative treatment for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen includes Imfinzi plus chemotherapy before surgery, followed by Imfinzi plus chemotherapy and then Imfinzi alone.
The CHMP’s positive opinion is based on the Phase III MATTERHORN trial, where the Imfinzi-based regimen cut the risk of disease progression, recurrence or death by 29% and reduced the risk of death by 22% versus chemotherapy alone. One- and two-year event-free survival rates and three‑year overall survival rates favored Imfinzi, with an overall survival benefit seen regardless of PD‑L1 status. Safety was similar between treatment arms, and surgery completion rates were comparable.
Imfinzi is already approved in this indication in the US and other countries based on MATTERHORN, and regulatory applications are under review in Japan and several additional markets. The decision positions Imfinzi as a potential first immunotherapy-based perioperative option for early gastric and GEJ cancers in the EU.
AstraZeneca PLC has begun trading its ordinary shares on the New York Stock Exchange, creating a harmonised global listing alongside its existing listings on the London Stock Exchange and Nasdaq Stockholm under the same AZN ticker. The company states this move opens access to the world’s largest capital market and broadens its global investor base.
Management highlights strong recent growth, citing pipeline readouts representing a stated peak revenue opportunity of over $10 billion and reiterating confidence in reaching a 2030 ambition of $80 billion in annual revenue and launching 20 new medicines. AstraZeneca’s UK and Swedish listings and index memberships remain unchanged, while its prior American Depositary Share listing ceased as ordinary share trading on the NYSE commenced, and its US dollar bonds are also transitioning to trade on the NYSE.
AstraZeneca PLC and AstraZeneca Finance LLC have filed Form 25 to voluntarily remove multiple securities from listing and registration on The Nasdaq Stock Market. The filing covers AstraZeneca American Depositary Shares representing one half of an ordinary share of 25¢ each, the underlying ordinary shares, and a wide range of AstraZeneca and AstraZeneca Finance senior notes with maturities from 2026 through 2051, many of which carry guarantees by AstraZeneca PLC. The companies certify they have complied with Nasdaq’s rules and the requirements of SEC Rule 12d2-2(c) for voluntary withdrawal, and the notification is signed by AstraZeneca PLC’s Company Secretary and an AstraZeneca Finance LLC Director on January 30, 2026.
AstraZeneca has entered a major collaboration with CSPC Pharmaceuticals to expand its weight management portfolio for obesity and type 2 diabetes across eight programmes. The deal gives AstraZeneca exclusive rights outside China to CSPC’s once-monthly injectable weight management portfolio, including clinical-ready GLP1R/GIPR agonist SYH2082 and three preclinical assets.
CSPC will receive an upfront payment of $1.2 billion, and is eligible for up to $3.5 billion in development and regulatory milestones, plus additional commercial milestones and tiered royalties. CSPC will lead development of four programmes through Phase I, after which AstraZeneca will take over development and commercialisation outside China. CSPC retains rights in China, Taiwan, Hong Kong and Macau, with an option for AstraZeneca to co-commercialise after approval. The transaction is expected to close in the second quarter of 2026, subject to customary conditions and regulatory clearances.
AstraZeneca plans to invest $15 billion in China through 2030 to expand medicines manufacturing and research and development. The company aims to strengthen capabilities in cell therapy and radioconjugates, supporting treatments for cancer, blood disorders, autoimmune diseases, and other conditions.
The investment will extend AstraZeneca’s China network from drug discovery and clinical development to large-scale production, building on existing R&D centers in Beijing and Shanghai and manufacturing sites in Wuxi, Taizhou, Qingdao, and Beijing. The company expects its highly skilled workforce in China to grow beyond 20,000, creating thousands of additional jobs across the healthcare ecosystem.